Lori A. Schretzman
Pfizer (United States)(US)
Publications by Year
Research Areas
Platelet Disorders and Treatments, Antiplatelet Therapy and Cardiovascular Diseases, Synthesis and Biological Evaluation, Synthesis and Characterization of Heterocyclic Compounds, Diabetes Treatment and Management
Most-Cited Works
- → Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor(1993)107 cited
- → Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists(1995)104 cited
- → Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture(1997)48 cited
- → Convergent, parallel synthesis of a series of β-substituted 1,2,4-oxadiazole butanoic acids as potent and selective αvβ3 receptor antagonists(2005)48 cited
- → A novel series of orally active antiplatelet agents(1995)32 cited
- → ChemInform Abstract: Inhibition of Human Cytomegalovirus Protease by Benzoxazinones and Evidence of Antiviral Activity in Cell Culture.(1997)